Since aberrant Nanog expression occurs in tumorigenesis, therapeutics targeted Nanog may improve the outcomes of patients with pancreatic cancer, thus suggesting the use of QYHJ to further improve preventive and therapeutic approaches in patients with this devastating disease. Here, NANOG is linked to pancreatic neoplasm.